Use is restricted to patients with blood eosinophils ≥150 cells/microlitre, and either ≥4 prior asthma exacerbations needing systemic corticosteroids in the previous 12 months or treatment with continuous oral corticosteroids over the previous 6 months.
Separately, NICE (TA565) has also recommended benralizumab for this indication although stipulated different parameters for initiation/eligibility.